30
Views
9
CrossRef citations to date
0
Altmetric
Antimicrobial Chemotherapy

The Impact of Prulifloxacin on Vaginal Lactobacillus Microflora: An In Vivo Study

Pages 646-650 | Published online: 18 Jul 2013

REFERENCES

  • Larsen B, Monif GR. Understanding the bacterial flora of female genital tract. Clin Infect Dis 2001; 32: 69–77.
  • Ronnqvist PD, Forsgren-Brusk UB, Grahn-Hakansson EE. Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH. Acta Obstet Gynecol Scand 2006; 85: 726–35.
  • Cherpes TL, Hillier SL, Meyn LA, Busch JL, Krohn MA. A delicate balance: risk factors for acquisition of bacterial vagi-nosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2008; 35 (1): 78–83.
  • Aroutcheva A, Gariti D, Simon M, Shutt S, Faro J, Simoes JA, et al. Defense factors of vaginal lactobacilli. Am J Obstet Gy-necol 2001; 185: 375–9.
  • Lepargneur JP, Rousseau V. Protective role of the Doder-leIn flora. J Gynecol Obstet Biol Reprod (Paris); 2002: 31 (5): 485–94.
  • Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Difference in the composition of vaginal microbial communities found in healthy Caucasian and black women. ISME J 2007; 1: 121–33
  • Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–14.
  • Hamilton-Miller JM, Shah S. Susceptibility patterns of vagi-nal lactobacilli to eleven oral antibiotics. J Antimicrob Chemother 1994; 33: 1059–60.
  • Hillier S, Holloway M, Rabe L. Antimicrobial agent sus-ceptibility of Lactobacillus crispatus, L. Jensen ii, L. gasseri, and other Lactobacillus species. In: Abstract of the Thirty-Ninth In-terscience Conference on Antimicrobial Agents and Chemother-apy, San Francisco, CA, Sept 26-29 1999, Abst. No. 2276.
  • Simoes JA, Aroutcheva AA, Shutt S, Faro S. Effect of metronidazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gynecol 2001; 9: 41–5.
  • Furneri PM, Mangiafico A, Giummarra V, Roccasalva LS, Tempera G. In vitro susceptibilities to various antibiotics of Lac-tobacillus spp. isolated from vagina. In: Abstracts of the 108th General Meeting of the American Society for Microbiology, June 1-5, Boston, MA., American Society for Microbiology, Wash-ington DC, USA, Abs. No. A-022
  • Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physi-cians. Arch Intern Med. 2002; 162: 41–7
  • Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient prac-tice, 1991-1999. Ann Intern Med 2003; 138: 525–33
  • Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for an-timicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29: 745–58
  • Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavu-lanate vs ciprofloxacin for the treatment of uncomplicated cysti-tis in women: a randomized trial. JAMA 2005; 293: 949–55
  • Boris S, Suarez JE, Vazquez F, Barbes C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interac-tion with uropathogens. Infect Immun 1998; 66: 1985–89
  • Hooton TM, Stamm WE. The vaginal flora and urinary tract infections. Urinary tract infections: molecular pathogenesis and clinical management. In: Molbey HLT, Warren JW, editors. Urinary tract Infections. Washington DC: ASM Press, 1996: 67-94
  • McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol. 1993; 6: 251–64
  • Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis. 1990 Sep-Oct; 12 (5): 856-72.
  • Reid, G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr. 2001; 73: 437S-43S
  • Edlund C, Nord CE. Effect on the human normal mi-croflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother. 2000; 46: 41–8.
  • Keam SJ, Perry CM. Prulifloxacin. Drugs. 2004; 64: 2221–34.
  • Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007; 21: 355–73.
  • Glover DD, Larsen B. Relationship of fungal vaginitis ther-apy to prior antibiotic exposure. Infect Dis Obstet Gynecol. 2003; 11: 157–60.
  • Fosch S, Fogolin N, Azzaroni E, Pairetti N, Dana L, Mi-nacori H, et al. Vulvovaginitis: correlation with predisposing factors, clinical manifestations and microbiological studies. Rev Argent Microbiol. 2006; 38: 202–5.
  • Sullivan A, Fianu-Jonasson A, Landgren BM, Nord CE. Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother. 2005; 49: 170–5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.